|Bid||2.80 x 2900|
|Ask||2.86 x 1200|
|Day's Range||2.8400 - 2.8700|
|52 Week Range||2.3400 - 6.4000|
|Beta (3Y Monthly)||1.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2019 - Mar 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
NEW YORK, Feb. 13, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
OPKO Health Inc NASDAQ/NGS:OPKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for OPK with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 6. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding OPK totaled $7.59 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
OPKO Health, Inc. (“OPKO Health” or the “Company”) (OPK) today announced the pricing of its offering of $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”). The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears at a rate of 4.50% per annum, and will mature on February 15, 2025, unless earlier repurchased, redeemed or converted. The Notes will be convertible into, at the Company’s election, cash, shares of the Company’s common stock, or a combination of cash and common stock, as further described in the prospectus supplement.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 4) AEterna Zentaris Inc. (NASDAQ: AEZS ) Axsome Therapeutics ...
SAN DIEGO , Feb. 5, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP is investigating potential claims against the following companies: AbbVie Inc. (NYSE: ABBV) [click here to join ...
OPKO Health, Inc. (“OPKO Health” or the “Company”) (OPK) today announced that, subject to market and other conditions, it intends to offer $200 million aggregate principal amount of Convertible Senior Notes due 2025 (the “Notes”) in an underwritten public offering. The Notes will be general senior unsecured obligations of the Company, will pay interest semiannually in arrears and will be convertible into, at the Company’s election, cash, shares of the Company’s common stock, or a combination of cash and common stock, as further described in the prospectus supplement.
The medical test and medication company is betting on the future of its 4Kscore diagnostic test, but has hit a roadblock.
MIAMI, Feb. 01, 2019 -- OPKO Health, Inc. (NASDAQ: OPK) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s point-of-care Sangia Total.
OPKO Health, Inc. (OPK) today announced an update on the ongoing development plans of OPK-88004, a selective androgen receptor modulator (SARM). OPK-88004 has the ability to serve as an antagonist to androgen receptors in the prostate, resulting in decreased prostate specific antigen (PSA) levels, and as an agonist resulting in increased anabolic effects, such as increased lean body mass and physical function and decreased fat mass.
OPKO Health, Inc. (OPK) today announced that Novitas Solutions, Inc. has issued a notice of a future non-coverage determination for the 4Kscore test® to be effective March 20, 2019. The notice released by Novitas today does not appear to be different from the draft local coverage determination released by Novitas on May 18, 2018. OPKO is evaluating options to appeal the decision and undertake other steps with the U.S. Centers for Medicare & Medicaid Services (CMS) in an effort to have this determination rescinded or reversed.
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...
BioReference Laboratories Inc., an OPKO Health Company (OPK), today announced that they will offer flexible payment arrangements for federal employees affected by the government shutdown. “We recognize the challenging financial position that federal government employees have faced throughout the shutdown,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. BioReference and its divisions, GenPath Diagnostics and GeneDx, developed a program to defer laboratory payments for 30 days to furloughed federal government employees.
The development is likely to boost Varian Medical's (VAR) Proton business that declined 12% year over year in the last reported quarter.
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.